Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
NCT05269667 · Hoffmann-La Roche · PHASE4 · terminated · last registry update 2025-01-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study has proved infeasible to recruit in sufficient numbers. There are insufficient eligible patients presenting to sites.” | – | Registry record, Hoffmann-La Roche |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-22Results posted on the registry: Takeda, TAK-500 + Pembrolizumab (NCT05070247)
- 2026-01-22Also stopped (terminated): Takeda, TAK-500 + Pembrolizumab (NCT05070247)
- 2026-01-13Phase 3 first posted: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, BMS-986353 + Fludarabine (NCT07335562)
- 2025-12-16Phase 3 first posted: Sanofi, Sarilumab + Sarilumab (NCT07286214)
- 2025-12-15Phase 3 first posted: Yale University, Anakinra + Tocilizumab (NCT07281027)
- 2025-12-04Phase 3 first posted: Capital Medical University, Tocilizumab + Placebo (NCT07263776)
- 2025-11-21Results posted on the registry: Hoffmann-La Roche, Nab-Paclitaxel + Gemcitabine (NCT03193190)
- 2025-11-13Also stopped (suspended): Massachusetts General Hospital, Tocilizumab + Placebo (NCT03787290)
- 2025-10-06Results posted on the registry: Biogen, BIIB800 + Actemra (NCT06262477)
- 2025-09-29Also stopped (withdrawn): BayCare Health System, Sarilumab 200 MG/1.14 ML Subcutaneous Solution + Placebo (NCT07196306)
- 2025-06-17Results posted on the registry: Cambridge University Hospitals NHS Foundation Trust, Rituximab + Infliximab (NCT05168475)
- 2025-06-17Also stopped (terminated): Cambridge University Hospitals NHS Foundation Trust, Rituximab + Infliximab (NCT05168475)
- 2025-06-12Results posted on the registry: Assistance Publique - Hôpitaux de Paris, Sarilumab (NCT04324073)
- 2025-06-12Results posted on the registry: Assistance Publique - Hôpitaux de Paris, Tocilizumab (NCT04331808)
- 2025-06-05Results posted on the registry: University of Chicago, Tocilizumab + Tocilizumab (NCT04479358)
- 2025-05-28Also stopped (terminated): Memorial Sloan Kettering Cancer Center, Tocilizumab (NCT04377659)
- 2025-03-04Also stopped (withdrawn): University of Florida, Satralizumab (NCT05727657)
- 2025-02-28Results posted on the registry: Hoffmann-La Roche, Satralizumab (NCT04963270)
- 2025-02-28Also stopped (terminated): Hoffmann-La Roche, Satralizumab (NCT04963270)
- 2025-02-18Phase 3 first posted: Insel Gruppe AG, University Hospital Bern, Prednisone + Prednisone (NCT06833411)
- 2025-02-10Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Tocilizumab (RoActemra®, 20 mg/mL). + Placebo (NaCl 0.9%) (NCT06818266)
- 2025-02-04Also stopped (terminated): National Cancer Institute (NCI), Tocilizumab (NCT04370834)
- 2024-12-27Results posted on the registry: Hoffmann-La Roche, satralizumab + azathioprine (AZA) (NCT04660539)
- 2024-12-18Results posted on the registry: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab Vedotin (NCT03677141)
- 2024-12-17Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), sarilumab (NCT03770273)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision